Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats

Journal of Hypertension

Volumn 28, Issue 6, 2010, Pages 1321-1329

  Yamamoto, Eiichiro ^a   Kataoka, Keiichiro ^a   Dong, Yi Fei ^a   Nakamura, Taishi ^a   Fukuda, Masaya ^a   Nako, Hisato ^a   Ogawa, Hisao ^a   Kim Mitsuyama, Shokei ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Aldosterone; Cardiac remodeling; L type calcium channel; Oxidative stress; Renal injury; T type calcium channel

Indexed keywords

ALDOSTERONE; AMLODIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CILNIDIPINE; DIHYDROPYRIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CARDITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GLOMERULOSCLEROSIS; HEART HYPERTROPHY; HEART INJURY; HEART MUSCLE FIBROSIS; HYPERTENSION; KIDNEY INJURY; KIDNEY TUBULE DISORDER; MALE; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77952548699     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283388045     Document Type: Article

References (40)

1. \+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. Eur J Pharmacol 2004; 498:303-314.
2. Namba M, Kim S, Zhan Y, Nakao T, Iwao H. Combination treatment with a calcium channel blocker and an angiotensin blocker in a rat systolic heart failure model with hypertension. Hypertens Res 2002; 25:461-466.
3. Wang N, Minatoguchi S, Chen XH, Arai M, Uno Y, Lu C, et al. Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein kinase C-dependent nitric oxide in rabbits. J Cardiovasc Pharmacol 2004; 43:747-757.
4. Yamashita T, Kawashima S, Ozaki M, Rikitake Y, Hirase T, Inoue N, et al. A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens 2001; 19:451-458.
5. Zhan Y, Kim S, Kawano H, Iwao H. Enhancement of glomerular platelet-derived growth factor beta-receptor tyrosine phosphorylation in hypertensive rats and its inhibition by calcium channel blocker. Hypertens Res 2002; 25:295-301.
6. Fukumoto Y, Yasuda S, Ito A, Shimokawa H. Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlodipine. J Cardiovasc Pharmacol 2008; 51:253-257.
7. Io K, Minatoguchi S, Nishigaki K, Ojio S, Tanaka T, Segawa T, et al. Effects of benidipine and some other calcium channel blockers on the prognosis of patients with vasospastic angina. Cohort study with evaluation of the ergonovine coronary spasm induction test. Arzneimittelforschung 2007; 57:573-581.
8. Nomura M, Nakaya Y, Uemura E, Sawa Y, Iga A, Kageyama N, et al. Effects of benidipine hydrochloride on autonomic nervous activity in hypertensive patients with high-and low-salt diets. Arzneimittelforschung 2003; 53:314-320.
9. Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, et al. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res 2007; 30:797-806.
10. Uzu T, Nishimura M, Fujii T, Sakaguchi M, Kanasaki M, Isshiki K, et al. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome. Hypertens Res 2007; 30:161-165.
11. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003; 83:117-161.
12. 2\+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100:342-353.
13. Van der Vring JA, Cleophas TJ, Van der Wall EE, Niemeyer MG. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far-a review of published data. T-Channel Calcium Channel Blocker Study Group. Am J Ther 1999; 6:229-233.
14. Hermsmeyer K, Mishra S, Miyagawa K, Minshall R. Physiologic and patho-physiologic relevanceofT-type calcium-ion channels: potential indications for T-type calcium antagonists. Clin Ther 1997; 19 (Suppl A):18-26.
15. Martinez ML, Heredia MP, Delgado C. Expression of T-type Ca(2\+) channels in ventricular cells from hypertrophied rat hearts. J Mol Cell Cardiol 1999; 31:1617-1625.
16. 2\+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994; 75:149-155.
17. Karam H, Clozel JP, Bruneval P, Gonzalez MF, Menard J. Contrasting effects of selective T-and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats. Hypertension 1999; 34:673-678.
18. 2\+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005; 45:241-246.
19. Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, et al. Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. Hypertension 2007; 50:657-662.
20. Yamamoto E, Lai ZF, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, et al. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens 2006; 24:2057-2069.
21. 2\+ channels in renal microcirculation. J Pharmacol Sci 2005; 99:221-227.
22. Nagase M, Kaname S, Nagase T, Wang G, Ando K, Sawamura T, Fujita T. Expression of LOX-1, an oxidized low-density lipoprotein receptor, in experimental hypertensive glomerulosclerosis. J Am Soc Nephrol 2000; 11:1826-1836.
23. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999; 10:2323-2331.
24. Wong PC, Hart SD, Zaspel AM, Chiu AT, Ardecky RJ, Smith RD, Timmermans PB. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther 1990; 255:584-592.
25. 2\+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584:424-434.
26. Hansen PB, Jensen BL, Andreasen D, Skott O. Differential expression of T-and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89:630-638.
27. Ito A, Fukumoto Y, Shimokawa H. Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J Cardiovasc Pharmacol 2004; 44:480-485.
28. Konda T, EnomotoA,Takahara A,Yamamoto H.Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 2006; 29:933-937.
29. 2\+ channel blocker cilnidipine in anesthetized dogs. Eur J Pharmacol 2007; 565:166-170.
30. Fujisawa T, Ikegami H, Noso S, Hiromine Y, Kawabata Y, Nishino M, et al. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy. J Diabetes Complications 2007; 21:252-257.
31. Morimoto S, Yano Y, Maki K, Iwasaka T. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J Hypertens 2007; 25:2178-2183.
32. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86:494-501.
33. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49:241-248.
34. Sun Y, ZhangJ, LuL, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161:1773-1781.
35. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51:161-167.
36. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 2001; 28:1002-1006.
37. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
38. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
39. Struthers AD, MacDonald TM. Review of aldosterone-and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61:663-670.
40. Yoshida K, Kim-Mitsuyama S, Wake R, Izumiya Y, Izumi Y, Yukimura T, et al. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005; 28:447-455.